Diabetic Nephropathy Online Journals

In United States and most developed countries Diabetic kidney disease and diabetic nephropathy are the leading in end-stage kidney disease. In USA 30% to 50% of incident cases on end-stage kidney diseases. Although this represents a significant public health concern, it is important to note that only 30% to 40% of patients with diabetes develop diabetic nephropathy. Specific treatment of patients with diabetic nephropathy can be divided into 4 major arenas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin-angiotensin system (RAS). Recommendations for therapy include targeting a hemoglobin A 1c concentration < 7% and blood pressure < 140/90 mm Hg with therapy anchored around the use of a RAS-blocking agent. The single best evidence-based therapy for diabetic nephropathy is therapy with a RAS-blocking medication. This Core Curriculum outlines and discusses in detail the epidemiology, pathophysiology, diagnosis, and management of diabetic nephropathy. Diabetic Nephropathy is a progressive kidney disease caused by damage to the capillaries in the kidney's glomeruli. It is characterized by nephrotic syndrome and diffuse scarring of glomeruli. It is longstanding diabetes and prime reason for dialysis in many developed countries.